CSE Bulletin: Delist - Core One Labs Inc. (COOL)
Core One Enters into Loan Agreement with Right Season Investments
Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
Core One Labs' Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods
Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer's and Parkinson's Disease
Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's Disease
Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic Compounds
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method
Core One Labs to Host Special Investor Webcast on Tuesday, January 18, 2022
Psychedelics Company Core One Labs Dives Into Functional Mushrooms With New $3M Acquisition
Core One Labs Applauds the City of Seattle in Their Efforts to Decriminalize Psylocibin and Other Natural Occuring Entheogenic Drugs
Core One Labs to Present on its Proprietary Biosynthetic Psilocybin Technology at Investor Town Hall Event on August 4, 2021
Core One Labs Announces Details of Consolidation to Meet Nasdaq Listing Requirements
REPEAT - New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
Core One Labs Retains Canada's Highest-Ranked IP Law Firm to Assist With Patent Filings
Core One Labs Plans Share Consolidation in Preparation of Listing its Common Shares on Nasdaq
REPEAT - Core One Labs' Biosynthesized Psilocybin Provisional Patent Imminent
Core One Labs' Biosynthesized Psilocybin Provisional Patent Imminent
Core One Labs Provides Clarification on Trading Activity
Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer's Disease
World Renowned Physician Joins Core One Labs as Chief Medical Officer
Core One Labs Unaware of Any Material Change that Would Account for Significant Share Price Depreciation
Core One Labs Completes Milestone Acquisition of Akome Biotech
Core One Labs Appoints Patent Expert, Dr. Dan Polonenko, To Advisory Board
Core One Labs Reaches Definitive Agreement to Acquire Akome Biotech
REPEAT -- Core One Labs to Explore Joint Venture with Lobe Sciences for the Clinical Development of Biosynthetic Psilocybin
Core One Labs to Explore Joint Venture with Lobe Sciences for the Clinical Development of Biosynthetic Psilocybin
Emerging Markets Report: The Rich Get Richer
Core One Labs Vocan Biotechnologies Enters into Collaborative Research Agreement with UBC
Core One Labs' Vocan Initiates Engineering and Design of a Proprietary Production System for Manufacturing of API-Grade DMT
Core One Labs Negotiates Milestone Acquisition With Akome Biotech Ltd.
Core One Labs to Rescind Share Exchange with Plant-Based Investment Corp.
Emerging Markets Report: A Moment for the Mushroom
Core One Labs Completes Acquisition of Ketamine Infusions Centers of Texas Representing the Company's First Psychedelics Clinic in the U.S. and Announces Fast Entry Inclusion in the Horizons Psychedelic ETF
Core One Labs Appoints Dr. Stephen Peach as Head of Patient Research
Core One Labs Files Application to List its Common Shares on NASDAQ
Core One Labs to Commence Trading in the US on OTC Pink Market
Psychedelic Expert Core One Labs Reports Milestone Acquisition
Core One Labs in Collaboration with KICT to Explore DMT Assisted Psychotherapy
Core One Labs Completes Sale of Non-Core Assets
Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to its Patented Thinstrip Delivery Method
Core One Labs Completes Acquisition of Vocan Biotechnologies Inc.